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The prognosis for patients with esophageal cancer remains poor. Therefore, the
identification of novel target molecules for the treatment of esophageal cancer is
necessary. Here, we investigated the clinicopathological significance of transcription
factor 4/transcription factor 7-like 2 (TCF4/TCF7L2) in resectable esophageal
squamous cell carcinoma (ESCC), because TCF4/TCF7L2 expression has not been
studied in esophageal cancer previously.
This study included 79 patients with esophageal cancer who underwent surgery
between 1998 and 2005. The expression of the TCF4/TCF7L2 protein in the nucleus
of esophageal cancer cells was analyzed using immunohistochemistry. We examined
the correlation between TCF4/TCF7L2 expression, clinicopathological factors, and
prognosis in patients with ESCC.
TCF4/TCF7L2 was expressed in 57 % (45/79) of patients. TCF4/TCF7L2 expression was
correlated with T factor (T1 vs. T2-4, p = 0.001), stage (I vs. II-IV, p =0.0058), Ly factor
(p =0.038), and V factor (p =0.038) and did not correlate with age, gender or N factor.
Furthermore, patients who were positive for TCF4/TCF7L2 had a significantly lower
survival rate than those who were negative for TCF4/TCF7L2 (log-rank test, p = 0.
0040). TCF4/TCF7L2 expression significantly affected the survival of patients with
ESCC. Positive expression of TCF4/TCF7L2 was correlated with a poor prognosis after
a curative operation in patients with ESCC.
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The prognosis of patients with esophageal cancer remains poor, emphasizing the need
for the development of new treatment strategies. Today, the overall 5-year survival rate
is less than 50 %, despite the use of multimodal therapies. Even in early-stage disease,
many patients develop a local recurrence of tumors or distant metastasis within a short
period of time after operation. To develop novel treatment strategies, it is important to
understand the biological behavior of esophageal cancer. Recent studies identified
several genes and molecules involved in the origin and/or progression of esophageal
cancer, including TP53 [1], deleted in esophageal cancer 1 (DEC1) [2], deleted in
colorectal cancer (DCC) [3], deleted in lung cancer 1 (DLC1) [4], cyclin D1 [5],© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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nisms that underlie the development and progression of esophageal squamous cell
carcinoma (ESCC) remain unclear.
The Wnt signaling pathway regulates important cellular processes, including develop-
ment and differentiation, apoptosis, immunologic and inflammatory responses, cell-
cycle progression and cellular division [8, 9]. Transcription factor 4/transcription factor
7-like 2 (TCF4/TCF7L2) is a key molecule of the Wnt signaling pathway, which acts as
a transcriptional factor in the nucleus [8, 10]. Downstream genes of the Wnt signaling
pathway include cyclin D1 and c-myc. To the best of our knowledge, no reports have
described the clinicopathological significance of TCF4/TCF7L2 protein expression in
the progression of various malignancies.
In this study, we investigated the clinicopathological significance of TCF4/TCF7L2
protein expression in 79 patients with resectable ESCC.Materials and methods
Tissue samples
Samples were obtained from 79 patients with ESCC who underwent operation at the
Department of Gastroenterological Surgery, Nagoya City University Medical School
between 1998 and 2005 without pre-operative chemotherapy or radiation. The tumors
were classified according to the guidelines for clinical and pathological studies on
carcinoma of the esophagus. The samples were used after obtaining written consent
from the patients.Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded
primary human ESCC tissues using the monoclonal anti-TCF4 antibody (Cell Signaling,
NY) at 1:200. Paraffin-embedded tumor sections were deparaffinized, rehydrated, heat-
treated by microwaving in 10 mM citrate buffer for 15 min for antigen retrieval, and
cooled to room temperature. The sections were then treated with 0.3 % H2O2 in
methanol for 30 min to neutralize the endogenous peroxidases, blocked with nonspe-
cific goat serum for 10 min, and incubated with the H-100 antibody overnight at room
temperature in a humid chamber. The immunoreactive protein was detected with a
DAKO Envision System, HRP (DAB), and sections were counterstained with
hematoxylin. Two independent investigators subjectively assessed the immunostaining
of TCF4, and discordant results were resolved by consultation with a third investigator.
For the evaluation of TCF4 expression, immunostaining was considered positive only
when unequivocally strong nuclear staining was present in more than 50 % of the
tumor cells, as analyzed using a light microscope. Cases with faint staining only were
considered negative.Statistical analysis
The chi-squared test was used to analyze the correlations between the clinicopathologi-
cal factors and the expression of TCF4/TCF7L2. The survival rates were calculated
according to the Kaplan-Meier method. Multivariate analysis of Cox’s proportional
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ences were considered statistically significant for P values less than 0.05.Results
Expression of TCF4/TCF7L2 in ESCC
First, we investigated the expression of the TCF4/TCF7L2 protein in ESCC tissues
using immunohistochemistry. Representative images of TCF4/TCF7L2 immunostaining
are shown in Fig. 1. Typical ESCC cells showed diffuse nuclear staining for TCF4/
TCF7L2, and the cell membrane and cytoplasm showed little to no staining. There is
almost no nuclear staining in normal esophageal mucosa of resected tissue (Fig. 1c).
Immunostaining for TCF4/TCF7L2 was positive in 56.9 % (45/79) of patients. TCF4/
TCF7L2 expression correlated significantly with the T factor, p-stage, lymphatic inva-
sion and vein invasion and did not correlate with the N factor (Table 1).Survival curves and expression of TCF4/TCF7L2
Next, we investigated the correlation between immunostaining for TCF4/TCF7L2 and
survival of patients with ESCC after surgery. TCF4/TCF7L2 had a significant effect on
patient survival (Fig. 2), and patients with positive staining for TCF4/TCF7L2 had signifi-
cantly shorter survival after surgery than patients with negative staining (16.7 ± 1.7 months
[n = 45] vs. 30.6 ± 2.6 months [n = 34], respectively; p = 0.004 by log-rank test; Fig. 2).
Univariate analysis showed that, among the clinicopathological factors examined in
this study, the extent of primary tumor (risk ratio, 4.184; p < 0.0001), lymph nodeFig. 1 Representative immunostaining for TCF4/TCF7L2. a – Positive staining for TCF4/TCF7L2 in tumor
cells. b – Negative staining for TCF4/TCF7L2 in tumor cells. c – Representative immunostaining for TCF4/
TCF7L2 in normal esophageal mucosa
Table 1 Correlation of TCF4 IHC in esophageal cancer with clinicopathological factors, including
patient and tumor characteristics
No. of patients (n = 79)
Characteristics Case TCF4(+) TCF4(−) p-value
Age at surgery
<65 years 44 25 19
>65 years 35 20 15 0.614
Gender
Male 63 35 28
Female 16 10 6 0.573
Tumor status
T1 15 3 12
T2 9 5 4
T3 32 19 13
T4 22 17 5
T1 vs T2-4 0.001
Lymph node status
N0 18 7 11
N1 61 38 23
N0 vs N1 0.078
Pathological stage
I 11 2 9
II 13 9 4
III 22 10 13
IV 32 23 9
I vs II-IV 0.0058
Lymphatic invasion
Negative 15 5 5/8
Positive 47 30 22/41
Unknown 16 0.038
Blood vessel invasion
Negative 28 11 13/21
Positive 34 24 14/28
Unknown 7 0.038
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vein invasion (risk ratio, 2.816; p = 0.0003), and immunostaining for TCF4/TCF7L2
(risk ratio, 2.506; p = 0.0049) were statistically significant prognostic factors. Multivari-
ate analysis revealed that TCF4/TCF7L2 expression was not an independent prognostic
factor (data not shown).
Discussion
The Wnt signaling pathway plays important roles in axis formation during early verte-
brate development [11]. Upon Wnt signaling, the phosphorylation of beta-catenin is
suppressed through undefined mechanisms, and beta-catenin functions as a transcrip-
tional regulator in the nucleus together with TCF4/LEF1 [12, 13]. A number of
Fig. 2 Kaplan-Meier survival curve for esophageal cancer patients, classified as either positive or negative
for TCF4/TCF7L2 immunostaining. TCF4/TCF7L2 status is strongly associated (log-rank, p = 0.0040) with
patient survival
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[16], and novel protein band 4.1 like 4 (NBL4) [17] have been reported; however, the
precise regulatory mechanisms remain to be resolved. Alterations of APC, AXIN, or beta-
catenin itself, lead to the accumulation of beta-catenin in the cytoplasm and/or nucleus,
resulting in the unregulated transcription of downstream genes [12–14, 16–18]. However,
in esophageal cancer cells, the frequency of beta-catenin accumulation in the nucleus is
lower than in colon and liver cancer [19]
TCF4/TCF7L2 is a major component of the Wnt signaling pathway. However, be-
cause few reports have described the mechanisms mediating Wnt signaling activa-
tion in ESCC, the factors that regulate TCF4/TCF7L2 expression in this type of
cancer are not known.
In many cancer cells, TCF4/TCF7L2 is localized to the nucleus [20]. Consistent with
this observation, our current experiments show that TCF4/TCF7L2 is also expressed in
the nucleus of ESCC cells (Fig. 1). In colon cancer cells, TCF4/TCF7L2 is located in the
nucleus with beta-catenin [20]. By contrast, for esophageal squamous cancer cells, our
data suggest that TCF4/TCF7L2 alone is located in the nucleus without beta-catenin,
because beta-catenin is not detected in the nucleus in ESCC [19]. However, the mecha-
nisms that regulate TCF4/TCF7L2 expression in ESCC remain unclear.
There are a few reports that the Wnt signaling pathway is activated in ESCC.
Cyclin D1, a downstream gene of the Wnt signaling pathway, is highly expressed
in ESCC [21, 22]. Other mechanisms of translocation to the nucleus for TCF4/
TCF7L2 may exist. Downstream genes of the Wnt signal pathway in esophageal
cancer may be activated by TCF4/TCF7L2 activation.
Because TCF4/TCF7L2 plays a role in cancer proliferation, additional studies are ne-
cessary to determine whether TCF4/TCF7L2 contributes to the growth of esophageal
cancers. In our study, TCF4/TCF7L2 was correlated with the T factor of patients with
ESCC (Table 1).
Interestingly, we found that TCF4/TCF7L2 predicted the prognosis of patients with
ESCC. Therefore, our data suggest that TCF4/TCF7L2 is involved in the cell prolifera-
tion of esophageal carcinoma and that TCF4/TCF7L2 is a useful biomarker for predict-
ing prognosis in patients with ESCC.
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prognosis or malignant potential in hepatocellular carcinomas [17] and colon can-
cer [11]. The current study may be the first report demonstrating that TCF4/
TCF7L2 is correlated with the prognosis of patients with esophageal squamous cell
carcinoma.
In this study, we found that increased expression of TCF4/TCF7L2 in the nucleus of
cancer tissue cells was accompanied by the local progression of esophageal cancer
(Fig. 1 and Table 2). In addition, patients with high nuclear expression of TCF4/
TCF7L2 had a poorer prognosis (Fig. 2).
Additionally, whether TCF4/TCF7L2 expression is mediated by other mechanisms
will be the focus of future studies.
In patients with esophageal cancer, many prognostic markers, including cyclin D1, E-
cadherin, and MDM2, have been reported [21, 23]. Furthermore, we also reported that
pituitary tumor transforming gene 1 (PTTG1) [24], DNA fragmentation factor 45
(DFF45) [25], NOTCH1 [15], VEGF-C [16], and DROSHA [26] may be prognostic
markers of ESCC. Therefore, TCF4/TCF7L2 represents an additional potential prognos-
tic indicator for patients with ESCC.
Although the precise molecular mechanisms through which TCF4/TCF7L2 is ac-
tivated must be clarified, our data clearly indicate that TCF4/TCF7L2 may be a
molecular target for the development of effective therapeutic agents for patients
with esophageal cancer.Table 2 Univariate analysis
Parameter Risk ratio 95 % CI p-value
Age at surgery
<65 years 1
>65 years 1.033 0.675-1.580 0.8814
Gender
Female 1
Male 1.057 0.628-1.777 0.8353
Primary tumor
T1-3 1
T4 4.184 2.610-6.711 <0.0001
Lymph node metastasis
N0 1
N1 4.149 2.242-7.692 <0.0001
Lymphatic invasion
Negative 1
Positive 6.622 2.398-18.18 0.003
Vein invasion
Negative 1
Positive 2.816 1.597-4.975 0.0003
Immunostaining for TCF4
negative 1
positive 2.506 1.321-4.739 0.0049
CI, confidence interval
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